AOD-9604 in Cicuco — Fat Loss Peptide Research Guide
AOD-9604 research guide for Cicuco. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't available on pharmacy shelves in Cicuco or anywhere else for that matter — this is a specialist compound distributed through a dedicated online market. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than any local market ever offers. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis showing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. Use this guide to evaluate AOD-9604 vendors rigorously — the framework here work regardless of your location.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Cicuco studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source AOD-9604 — Vendor Guide
Before evaluating any specific vendor, build a clear picture of what a proper COA looks like — so you can identify whether a supplier meets the standard. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. Positive vendor signals beyond COA quality: documented vendor history spanning multiple years, knowledgeable support capable of explaining COA data, and temperature-appropriate packaging with desiccant. Price is an poor proxy for AOD-9604 quality — research-grade synthesis and testing has real costs that do not compress without quality compromise, so the lowest-priced options almost always involve trade-offs.
Order AOD-9604 — ships to Cicuco
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bacteriostatic water. Bacterial endotoxin contamination is the greatest safety hazard specific to research peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on AOD-9604 should be reviewed carefully before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
